汇宇制药(688553.SH)：注射用紫杉醇(白蛋白结合型)获得境外上市许可

智通财经2025-10-31

智通财经APP讯，汇宇制药(688553.SH)发布公告，公司子公司Seacross(Europe) Pharma Ltd.和Seacross Pharmaceuticals Ltd.于近期分别收到葡萄牙药品和保健品管理局、英国药品和健康产品管理局核准签发的公司产品注射用紫杉醇(白蛋白结合型)的上市许可。注射用紫杉醇(白蛋白结合型)主要单药疗法适用于治疗成人转移性乳腺癌患者(这些患者在一线治疗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2579430841?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-31 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579430841","market":"fut","top_or_hot":-1,"title":"汇宇制药(688553.SH)：注射用紫杉醇(白蛋白结合型)获得境外上市许可","media":"智通财经","content":"<div>\n<p>智通财经APP讯，汇宇制药(688553.SH)发布公告，公司子公司Seacross(Europe) Pharma Ltd.和Seacross Pharmaceuticals Ltd.于近期分别收到葡萄牙药品和保健品管理局、英国药品和健康产品管理局核准签发的公司产品注射用紫杉醇(白蛋白结合型)的上市许可。注射用紫杉醇(白蛋白结合型)主要单药疗法适用于治疗成人转移性乳腺癌患者(这些患者在一线治疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1363596.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>汇宇制药(688553.SH)：注射用紫杉醇(白蛋白结合型)获得境外上市许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n汇宇制药(688553.SH)：注射用紫杉醇(白蛋白结合型)获得境外上市许可\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-31 15:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1363596.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，汇宇制药(688553.SH)发布公告，公司子公司Seacross(Europe) Pharma Ltd.和Seacross Pharmaceuticals Ltd.于近期分别收到葡萄牙药品和保健品管理局、英国药品和健康产品管理局核准签发的公司产品注射用紫杉醇(白蛋白结合型)的上市许可。注射用紫杉醇(白蛋白结合型)主要单药疗法适用于治疗成人转移性乳腺癌患者(这些患者在一线治疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1363596.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1363596.html","article_id":"2579430841","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579430841","pubTimestamp":1761896209,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，汇宇制药 发布公告，公司子公司Seacross Pharma Ltd.和Seacross Pharmaceuticals Ltd.于近期分别收到葡萄牙药品和保健品管理局、英国药品和健康产品管理局核准签发的公司产品注射用紫杉醇的上市许可。公司注射用紫杉醇研发成功后已进行了多国注册申报，目前已在英国、葡萄牙、丹麦、荷兰、爱尔兰、芬兰、瑞典获得上市许可。截至目前，公司已在包含意大利、法国、西班牙等7个国家提交注册申请。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688553":"汇宇制药-W","BK0239":"医药制造"},"translate_title":"Huiyu Pharmaceutical (688553. SH): Paclitaxel for injection (albumin-bound type) obtained overseas marketing authorization","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688553":1.5},"content_text":"智通财经APP讯，汇宇制药(688553.SH)发布公告，公司子公司Seacross(Europe) Pharma Ltd.和Seacross Pharmaceuticals Ltd.于近期分别收到葡萄牙药品和保健品管理局、英国药品和健康产品管理局核准签发的公司产品注射用紫杉醇(白蛋白结合型)的上市许可。注射用紫杉醇(白蛋白结合型)主要单药疗法适用于治疗成人转移性乳腺癌患者(这些患者在一线治疗转移性疾病后病情未见好转，且标准的含蒽环类药物治疗方案不适用);与吉西他滨联合使用适用于成人转移性胰腺腺癌患者的首次治疗;与卡铂联合使用，适用于不适合接受可能具有治愈效果的手术和/或放疗的成年非小细胞肺癌患者的初始治疗。公司注射用紫杉醇(白蛋白结合型)研发成功后已进行了多国注册申报，目前已在英国、葡萄牙、丹麦、荷兰、爱尔兰、芬兰、瑞典获得上市许可。截至目前，公司已在包含意大利、法国、西班牙等7个国家提交注册申请。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579430841","isCrawlerRequest":true}